Navigation Links
Advanced Health Media Acquires Advogent
Date:2/2/2010

BRIDGEWATER, N.J., Feb. 2 /PRNewswire/ -- Advanced Health Media, LLC (AHM), the leading U.S. provider of pharmaceutical sales, marketing and compliance technology and services, announced it has acquired substantially all of the assets of Advogent Group, Inc. (Advogent), a Piscataway, NJ-based provider of marketing services for the pharmaceutical industry. Integration of the companies will begin immediately and headquarters will remain at AHM's Bridgewater, N.J. office. Terms of the agreement were not disclosed.

The addition of Advogent's services and customers expands AHM's market presence and leadership and provides a foundation for ongoing business growth, while offering pharmaceutical industry customers the broadest possible suite of marketing and relationship management services that comply with all federal and state regulations. "This acquisition solidifies AHM's market leadership position in speaker bureau management and marketing communications," said Kevin McMurtry, Founder and CEO of Advanced Health Media. "The combined business will be one of the largest marketing services and technology suppliers in the pharmaceutical industry. Our scale and breadth of services will be a competitive advantage for AHM and its customers."

"We are excited about the integration of these two organizations," said Jeff Brady, President of AHM.  "AHM and Advogent have each established proven track records for exceptional service to their customers.  Our expanded organization has the scale and experience needed to provide our clients the highest levels of service in an increasingly complex promotional environment."  

About Advanced Health Media, LLC

Advanced Health Media (AHM) is the leading U.S. provider of speaker-led meeting logistics, state and federal regulatory compliance technology, thought leader development and medical communications. AHM offers a fully integrated suite of hosted technology solutions and sales support services designed to address the diverse operational and compliance management needs of its clients, including corporate speaker bureau and event management solutions, sales force automation technology, customer relationship management and compliance tracking and reporting systems.  AHM also provides full-service medical communications, including strategic communication strategy, publication planning, scientific meetings and key opinion leader advocacy development. AHM provides services to more than 50 companies in the pharmaceutical sector.

Headquartered in Bridgewater, NJ, with offices in Union and Somerville, NJ, Chesapeake, VA, and Chicago, IL, AHM is the parent company of AHM Solutions, Centeon Solutions, Embryon, LLC, Cogenix, LLC, ProMedix, LLC, InsiteResearch, LLC and Ephikacy, LLC. For more information, please visit the AHM Web site at www.ahmdirect.com.

About Advogent Group, Inc.

Advogent Group, Inc. creates, delivers, and manages compliant communications and strategic solutions and services for pharmaceutical, biotechnology, and medical device companies. The company offers strategic publication services; and healthcare communications, including advocacy development and management, message delivery and management, and content creation. It also provides event management and logistics, and compliant data systems. The company was founded in 2007 and is headquartered in Piscataway, New Jersey. Advogent Group, Inc. is a former subsidiary of Cardinal Health, Inc.

SOURCE Advanced Health Media, LLC

RELATED LINKS
http://www.ahmdirect.com

'/>"/>

SOURCE Advanced Health Media, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
4. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
5. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
11. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... 2017 AVACEN Medical , Inc. (AVACEN) announced ... 2017 New Product Innovation Award for Its fibromyalgia pain ... secondary medical device market research by Frost & Sullivan,s industry ... drug-free pain relief product, the AVACEN 100, offers a safe ... widespread pain. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... the nation's first interactive health literacy software tool, and the Cancer Patient Education ... of cancer patient education, today announce a new strategic alliance. , As ...
Breaking Medicine News(10 mins):